A groundbreaking clinical trial is offering new hope to a Bairnsdale man battling recurrent prostate cancer. Gerrit van Rijswijk has become the first patient at Latrobe Regional Health (LRH) to undergo a cutting-edge radiation therapy treatment, bringing a glimmer of light to those affected by this disease.
Gerrit's story is one of resilience and determination. After initially being diagnosed with prostate cancer in 2015, he bravely underwent eight weeks of radiation therapy at LRH. However, the battle was far from over. In 2022, follow-up blood tests revealed that the cancer had returned, but this time, it was confined to the prostate. This is where the SABR trial steps in.
Stereotactic Ablative Body Radiation Therapy (SABR) is a remarkable innovation in cancer treatment. It delivers a precise, high-dose radiation treatment directly to the prostate while minimizing exposure to surrounding tissues. The trial, conducted in partnership with The Alfred, offers a five-session treatment plan, providing a second chance at a cancer-free life for patients like Gerrit.
The trial is specifically designed for patients with recurrent prostate cancer that has spread to the prostate, who have previously undergone radiation therapy. In the past, these patients faced a grim prognosis, with limited treatment options available. But with SABR, there is a glimmer of hope.
Gerrit's journey is a testament to the power of medical advancements. His initial diagnosis and treatment at LRH set the stage for this new chapter. As he embarks on the SABR trial, he becomes a beacon of inspiration for others facing similar challenges. The trial's success could pave the way for more patients to benefit from this innovative approach.
The trial's accessibility is a significant advantage for patients from Gippsland. By utilizing the Teletrial model, patients can receive treatment at LRH without the burden of traveling to Melbourne. This not only reduces the financial and physical strain but also provides a sense of comfort and familiarity.
Gerrit's enthusiasm for the trial is infectious. He expresses excitement about the potential benefits it could bring to others, highlighting the importance of bringing specialized care closer to home. This approach not only improves patient well-being but also addresses the challenges faced by regional and rural patients, who often face financial and logistical hurdles in accessing treatment.
The SABR trial at LRH is just the beginning. Dr. Therese Kang, a Radiation Oncologist at The Alfred and a Prostate SABR fellow at LRH, is leading a series of trials that will expand access to this cutting-edge treatment. The support from organizations like the Australian Teletrial Program, TrialHub, and the Radiation Therapy Network is crucial in making these trials a reality.
Latrobe Regional Health's commitment to bringing innovative treatments to Gippsland residents is evident. Since launching their clinical trials program in 2019, they have been dedicated to providing high-quality research opportunities, ensuring that patients can receive the best care possible, right in their own communities. This initiative not only improves patient outcomes but also strengthens the healthcare system by fostering collaboration and innovation.
